A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer

Clinical trial NCT02789345 · COMPLETED

Trial details

NCT number: NCT02789345
Sponsor: Eli Lilly and Company
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Non-small Cell Lung Cancer

Start date: 2016-10-24
Primary completion: 2017-10-19
Enrollment: 29

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.